CDK

ADC Related

ADC Antibody ADC Cytotoxin ADC Linker ADCs Drug-Linker Conjugates for ADC
Angiogenesis

5-alpha Reductase ALK Bcr-Abl BTK EGFR FAK FLT3 HER-2 HIF Src Syk VDA VEGFR
Anti-infection

Antibiotic Arenavirus Bacterial CMV EBV Enterovirus Filovirus Fungal Gli HBV HCV HCV Protease HIV HSV Influenza Virus Parasite RABV Reverse Transcriptase RSV SARS-CoV TMV Virus Protease
Apoptosis

Apoptosis ASK Bcl-2 Caspase c-Myc c-RET Cytohesin DAPK Ferroptosis FKBP IAP Mdm2 p53 PD-1 PD-L1 PERK PKD Ras RIP kinase ROS Survivin Thymidylate Synthase TNF Receptor TNFa TRADD
Autophagy

Autophagy LRRK2 Mitophagy OGA ULK
Cell Cycle

Antifolate APC Aurora Kinase BMI-1 CDK Chk c-Myc Eukaryotic Initiation Factor G-quadruplex HDAC HSP Kinesin LIMK Mad2 Microtubule(Tubulin) Mps1 Nucleoside Antimetabolite/Analog Nur77 p21 PAK PERK PFKFB PLK PPAR Ras Rho ROCK SRPK TOPK Topoisomerase Wee1
Cytoskeletal Signaling

Arp2 3 Complex Bcr-Abl Cardiac Myosin Dynamin Gap Junction Protein HSP Integrin Kinesin Microtubule Associated MLCK Myosin PAK TACC3 Wntbeta-catenin
DNA Damage

ATM(ATR) CRISPR(Cas9) DNA alkylator DNA Stain DNA(RNA) Synthesis GAK HDAC HSP Nucleoside Antimetabolite(Analog) OGG1 p97 PARG PARP RAD51 RNR Sirtuin SMN Telomerase Topoisomerase
Endocrinology & Hormones

5-alpha Reductase ACE Adrenergic Receptor Androgen Receptor Aromatase Estrogenprogestogen Receptor Glucocorticoid Receptor GPR Mineralocorticoid Receptor RAAS THR TSH Receptor
Epigenetics

AMPK Aurora Kinase DNA Methyltransferase Epigenetic Reader Domain EZH1 2 HDAC HIF Histone Acetyltransferase Histone Demethylase Histone Methyltransferase JAK MAT MicroRNA MLL Pim PKC Protein Arginine Deiminase Sirtuin Small Interfering RNA (siRNA) SMYD

+MORE

CDK

CDKs (Cyclin-dependent kinases) are serine-threonine kinases first discovered for their role in regulating the cell cycle.Additionally, they control mRNA processing, transcription, and nerve cell differentiation. With molecular weights between 34 and 40 kDa, CDKs are relatively small proteins that only contain the kinase domain. In fact, when their CDK gene has been replaced with the homologous human gene, yeast cells can proliferate normally. A CDK by definition binds the control protein cyclin. Only the cyclin-CDK complex is an active kinase; CDK lacks much kinase activity on its own.

Around 20 Cyclin-dependent kinases (CDK1-20) have been identified as of yet. While CDK 7, 8, 9 and 11 are linked to transcription, CDK1, 4, and 5 are involved in the cell cycle.

The majority of CDK regulation occurs post-translationally, and CDK levels are essentially constant throughout the cell cycle. The majority of knowledge about CDK structure and function is based on CDKs from vertebrates (CDC2 and CDK2), S. pombe (CDC28), and S. cerevisiae (Cdc2). Cyclin binding, CAK phosphorylation, regulatory inhibitory phosphorylation, and CDK inhibitory subunit (CKI) binding are the four main mechanisms of CDK regulation.

CDK related products

Cat No.	Product Name	CAS No.	Product Description
V24310	hSMG-1 inhibitor 11j	1402452-15-6	hSMG-1 inhibitor 11j, a pyrimidine analogue, is a potent and specific hSMG-1 inhibitor (antagonist) with IC50 of 0.11 nM.
V51040	Indirubin-3-oxime (IDR-3O)	667463-82-3	Indirubin-3′-oxime (IDR3O), a synthetic indirubin derivative, is a novel inhibitor of glycogen synthase kinase 3β (GSK3β) and cyclin-dependent kinases (CDKs).
V55077	Inixaciclib	2370913-42-9	Inixaciclib is a potent CDK inhibitor that may be utilized in anti-cancer research.
V85794	INX-315	2745060-92-6
V51944	Ipivivint	1481617-15-5	Ipivivint (compound 38) is a potent CDC-like kinase (CLK) inhibitor (antagonist) with EC50s of 1 nM and 7 nM for CLK2 and CLK3, respectively.
V51930	IV-361	2055741-39-2	IV-361 is an orally bioactive, selective CDK7 inhibitor (Ki≤50 nM).
V85475	JA397
V53248	JH-XVI-178	2648453-53-4	JH-XVI-178 is a potent and specific CDK8/19 inhibitor (antagonist) with low clearance and moderate oral pharmacokinetic properties.
V92030	JSH-009	2247481-08-7	JSH-009 is a novel, highly selective inhibitor of CDK9, which is critical for regulating transcription elongation.
V92031	JSH-009 dimaleate	2559759-04-3	JSH-009 dimaleate (Compound 1) is a potent and highly selective CDK9 inhibitor with IC50 of 0.928 nM.
V22999	JSH-150	2247481-21-4	JSH-150 is a potent and specific CDK9 inhibitor (antagonist) with IC50 of 1 nM.
V51912	K00546	443798-47-8	K00546 is a potent CDK1 and CDK2 inhibitor (antagonist) with IC50s of 0.6 nM and 0.5 nM for CDK1/cyclin B and CDK2/cyclin A, respectively.
V1536	K03861 (AUZ 454)	853299-07-7	K03861 (K0 3861;AUZ-454;K-03861;AUZ 454), an aminopyrimidine-phenyl urea analog, is novel and potent type IIcyclin-dependent kinase-CDK2 inhibitor with potential anticancer activity.
V51906	KB-0742 dihydrochloride	2416874-75-2	KB-0742 di-HCl is a specific and orally bioactive CDK9 inhibitor (antagonist) with IC50 of 6 nM against CDK9/cyclin T1.
V51903	KH-CB20	1354448-60-4	KH-CB20, an E/Z mixture, is a potent and specific inhibitor of CLK1 and the closely related isoform CLK4, with IC50 for CLK1 inhibition of 16.5 nM.
V84703	KuWal151	2341841-06-1
V1544	LDC000067 (LDC067)	1073485-20-7	LDC000067 (also called LDC-000067;LDC-067) is a novel, potent, highly selective and ATP-competitive inhibitor ofcyclin-dependent kinase (CDK9)with potential antineoplastic activity.
V2731	LDC4297	1453834-21-3	LDC4297 is a novel and potentCDK7 (Cyclin-dependent protein kinase 7) inhibitor with IC50 of 0.13±0.06 nM for CDK7and IC50s between 10 nM and 10,000 nM for all other analyzed CDKs.
V51877	LDC4297 hydrochloride	2319747-14-1	LDC4297 HCl is a selective inhibitor of CDK7 with IC50 of 0.13 nM.
V3925	RIBOCICLIB SUCCINATE (LEE011)	1374639-75-4	Ribociclib succinate (LEE011; NVP-LEE-011; LEE-011, NVP-LEE011; Kisqali), the succinate salt of Ribociclib, is a CDK4/6 (cyclin-dependent kinase) inhibitor (IC50s = 10 nM and 39 nM) approved in March 2017 by FDA for the treatment of breast cancer.